title: Mastabol induced acute cholestasis: A case report.
abstract: A 26-year-old male presented with three weeks of jaundice after the self-initiation of the injectable anabolic steroid, Mastabol [Dromastanolone Di-Propionate (17 beta-Hydroxy-2alpha-methyl-5alpha-androstan-3-one propionate)]. He reported dark urine, light stools, and pruritus. He denied abdominal pain, intravenous drug use, intranasal cocaine, blood transfusions, newly placed tattoos, or sexually transmitted diseases. He used alcohol sparingly. Physical exam revealed jaundice with deep scleral icterus. The liver was palpable 2 cm below the right costal margin with no ascites. The peak bilirubin was 23.6 mg/dL, alkaline phosphatase was 441 units/L, and aspartate aminotransferase/alanine aminotransferase were 70 units/L and 117 units/L respectively. A working diagnosis of acute intrahepatic cholestasis was made. Liver biopsy revealed a centrilobular insult with neutrophilic infiltrates and Ito cell hyperplasia consistent with acute drug induced cholestasis. The patient's clinical symptoms resolved and his liver enzymes, bilirubin, and alkaline phosphatase normalized. Anabolic steroids with 17 alpha carbon substitutions have been associated with a bland variety of cholestatic injury with little hepatocellular injury. Cholestasis, under these circumstances, may be secondary to the binding of drugs to canalicular membrane transporters, accumulation of toxic bile acids from canalicular pump failure, or genetic defects in canalicular transport proteins. Mastabol is an injectable, 17 beta hydroxyl compound with no alpha alkyl groups at the 17 carbon position. As such, it has been reported to have little potential toxic effects on the liver. This is the first known reported case of Mastabol-induced cholestatic liver injury. It highlights the need for physicians to consider such widely available substances when faced with hepatic injury of unclear etiology.
authors.affiliation: Brett M Hymel, Department of Gastroenterology, Louisiana State University School of Medicine, New Orleans, LA 70112, United States.
authors.forename: Brett M
authors.initials: BM
authors.lastname: Hymel
authors.forename: David W
authors.initials: DW
authors.lastname: Victor
authors.forename: Luis
authors.initials: L
authors.lastname: Alvarez
authors.forename: Nathan J
authors.initials: NJ
authors.lastname: Shores
authors.forename: Luis A
authors.initials: LA
authors.lastname: Balart
keywords: Anabolic; Cholestatic; Hepatic; Mastabol; Steroids
references.citation: Gut. 1973 Apr;14(4):332-9
references.pmid: 4574904
references.citation: Br J Sports Med. 2007 Jul;41(7):462-3
references.pmid: 17224443
references.citation: Dtsch Med Wochenschr. 1999 Sep 10;124(36):1029-32
references.pmid: 10506840
references.citation: Liver Int. 2011 Mar;31(3):348-53
references.pmid: 21040407
references.citation: Br J Sports Med. 2005 May;39(5):e27
references.pmid: 15849280
references.citation: J Clin Gastroenterol. 2002 Oct;35(4):350-2
references.pmid: 12352300
references.citation: Clin Gastroenterol Hepatol. 2007 Jul;5(7):809-12
references.pmid: 17509944
references.citation: Blood. 1969 Sep;34(3):283-300
references.pmid: 5820048
references.citation: Clin Ther. 2001 Jun;23(6):789-801; discussion 771
references.pmid: 11440282
references.citation: HIV Hotline. 1998 Dec;8(5-6):2-5
references.pmid: 11366381